Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma 3Sarcoma, Synovial 2Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasms, Germ Cell and Embryonal 1Melanoma 1Medulloblastoma 1Liposarcoma, Myxoid 1Hepatoblastoma 1Fallopian Tube Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Brain Neoplasms 1Bone Neoplasms 1Advanced Fallopian Tube Carcinoma 1

Interventions

adacel 1Tetanus Toxoid 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Leukapheresis 1Diphtheria-Tetanus-acellular Pertussis Vaccines 1Diphtheria-Tetanus Vaccine 1Diphtheria Toxoid 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Fallopian Tube Carcinoma × Leukapheresis × Sarcoma × Clear all
NCT06639074 2025-10-02

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Mayo Clinic

Phase 2 Recruiting
78 enrolled
GynecologicSarcoma

Advanced Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡